MedTrace Logo

Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease

NCT00598637 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2013-07-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of two different drug-eluting stents (Everolimus and Zotarolimus-eluting) for treatment of unprotected left main coronary artery disease.

Conditions

  • Coronary Disease

Interventions

DEVICE

Everolimus-eluting stent (Xience)

stent is implanted due to randomization

DEVICE

Zotarolimus-eluting stent (Endeavor Resolute)

stent is implanted due to randomization

Sponsors & Collaborators

  • Technical University of Munich

    collaborator OTHER

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Adnan Kastrati, MD · Deutsches Herzzentrum Muenchen

  • Julinda Mehill, MD · Deutsches Herzzentrum Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2012-09-30
Completion
2013-02-28

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00598637 on ClinicalTrials.gov